Under construction – not a live service
Sign in
Taking people in ChinaPhase 1/2

Tests JAB-21822 in lung cancer with KRAS G12C and STK11 changes

Tests JAB-21822 in adults with advanced lung cancer carrying KRAS and STK11 changes.

Key facts

Who runs it
Allist Pharmaceuticals, Inc.
Where
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Harbin, Hohhot, Hubei, Nanning, Shenyang, Shenzhen, Shijiazhuang, Xi’an, Xiamen, and Zhengzhou, ChinaSee the 21 sites
Trial code
Registry title
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Status
Recruiting
Phase
Phase 1/2
People taking part
104 people, planned
Started
17 Aug 2022
Expected to end
Aug 2027
Type of study
Interventional, 3 groups
Treatments tested
  • JAB 21822
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic non-small cell lung cancer. Their tumor must have a KRAS p.G12C change and an STK11 co-mutation, with normal (wild-type) KEAP1.

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-small cell lung cancer that is locally advanced or has spread (metastatic), confirmed by tissue testing
Earlier treatment
Can be untreated, or have had at least 1 prior standard therapy for advanced NSCLC
Biomarker or test result
KRAS p.G12C mutation, STK11 co-mutation and wild-type KEAP1 (confirmed locally)

Main reasons for not taking part

  • Cancer spread to the brain or meninges, unless treated and stable for at least 28 days
  • Any severe or uncontrolled medical condition
  • Active infection needing systemic treatment within 7 days
  • Radiation therapy within 3 weeks of study day 1

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing
  • STK11 co-mutation and KEAP1 Wild-Type (local confirmation)
  • Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC
  • ECOG 0-1

Who cannot take part

  • Therapeutic radiation therapy within 3 weeks of study day 1
  • Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days
  • Any severe and/or uncontrolled medical conditions
  • Active infection requiring systemic treatment within 7 days

Where in China

  • Beijing, Beijing MunicipalityHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Beijing, Beijing MunicipalityHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Beijing, Beijing MunicipalityHospital not named in the registryContact: Wang Jie Wang Jie M.D., M.D.Taking people
  • Beijing, Beijing MunicipalityHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Beijing, Beijing MunicipalityHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Beijing, Beijing MunicipalityHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Changchun, JilinHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Changsha, HunanHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Chongqing, Chongqing MunicipalityHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Hangzhou, ZhejiangHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Harbin, HeilongjiangHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Hohhot, NeimengguHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Hubei, WuhanHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Nanning, GuangxiHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shenyang, LiaoningHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shenyang, LiaoningHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shenzhen, GuangdongHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shijiazhuang, HebeiHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Xi’an, ShanxiHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Xiamen, FujianHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Zhengzhou, HenanHospital not named in the registryContact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting

About the trial

What the trial wants to find out

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

The 3 groups in the trial

  • Phase 1 ,Dose Exploration ,monotherapyTreatment being tested

    Dose escalation of JAB21822 will be administered as monotherapy to determine the MTD and RP2D

    Treatment: JAB 21822

  • Phase 2, Dose Expansion, Part1 monotherapyTreatment being tested

    Part 1 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects with previously untreated advanced non-small cell lung cancer (NSCLC)

    Treatment: JAB 21822

  • Phase 2 Dose Expansion, Part 2 monotherapyTreatment being tested

    Part 2 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects who had received at least one previous line of systemic therapy for NSCLC

    Treatment: JAB 21822

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Plain-language title
Tests JAB-21822 in lung cancer with KRAS G12C and STK11 changesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 August 2026